Orion Portfolio Solutions LLC Increases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Orion Portfolio Solutions LLC increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 36.8% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 30,625 shares of the specialty pharmaceutical company’s stock after acquiring an additional 8,235 shares during the period. Orion Portfolio Solutions LLC’s holdings in Jazz Pharmaceuticals were worth $3,771,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New Age Alpha Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $183,000. Blair William & Co. IL increased its stake in Jazz Pharmaceuticals by 25.2% during the 4th quarter. Blair William & Co. IL now owns 2,531 shares of the specialty pharmaceutical company’s stock worth $312,000 after buying an additional 509 shares during the period. Loomis Sayles & Co. L P increased its stake in Jazz Pharmaceuticals by 59.0% during the 4th quarter. Loomis Sayles & Co. L P now owns 169,621 shares of the specialty pharmaceutical company’s stock worth $20,889,000 after buying an additional 62,969 shares during the period. NEOS Investment Management LLC acquired a new position in Jazz Pharmaceuticals in the 4th quarter worth $206,000. Finally, Sava Infond d.o.o. purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $421,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Down 2.8 %

NASDAQ:JAZZ opened at $122.92 on Monday. The firm has a market capitalization of $7.47 billion, a P/E ratio of 17.31, a P/E/G ratio of 1.04 and a beta of 0.44. The business has a 50 day simple moving average of $132.30 and a 200 day simple moving average of $122.66. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,736 shares of company stock valued at $4,022,825. 4.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on JAZZ. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Piper Sandler reiterated an “overweight” rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Morgan Stanley reissued an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price target for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Buy” and an average target price of $187.71.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.